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Significance of MDR1-Gene and P-Glycoprotein (P-gp) Expressions 
in the Lesional Skin of Psoriasis Vulgaris
Yoko ABE, Kazuhiro SHIMIZU, Ichiro KATAYAMA
Department of Dermatology, Nagasaki University School of Medicine
 We have examined P-gp (P-glycoprotein) and multi-drug 
resistance 1 (MDR1) gene expressions in the lesional skin of 
psoriasis vulgaris and atopic dermatitis some of those 
showed a decreased clinical response to topical corticosteroid 
ointment during the clinical course. 
 The patients were subdivided into four groups; S (-): re-
sponder to topical steroid without steroid ointment for one 
month at the time of biopsy, S (+): responder to topical ster-
oid and under steroid therapy at the time of biopsy, R (-): 
low or non- responder to topical steroid without steroid 
therapy for one month at the time of biopsy, R (+): low-or 
non-responder to topical steroid and under steroid therapy 
at the time of biopsy. 
 P-gp was mainly expressed in the cytoplasm of some epi-
dermal keratinocytes and most of infiltrating cells in the 
dermis of the lesional skin of psoriasis or atopic dermatitis. 
Scores of P-gp protein-expression was significantly higher 
in the patients under steroid ointment both in psoriasis 
vulgaris and atopic dermatitis. While R (+) group showed 
much more intense expression of P-gp than S (+) group in 
psoriasis vulgaris but this was not the case for atopic der-
matitis. 
 MDR1 gene was expressed in the lesional skin of R (+) 
psoriasis but not in S (+) psoriasis or normal skin. 
 These results suggest that steroid-resistance occasionally 
experienced in psoriasis vulgaris might be related to the 
overexpression of P-gp which is possibly induced after topi-
cal steroid ointment. This might provide a new insight for 
the mechanism of steroid -insensitivity in inflammatory 
skin disorders especially in psoriasis vulgaris. 
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Introduction
 Although several side effects were recognized, topi-
cal glucocorticosteroids (GC) ointment is the most 
widely used medication in the treatment of skin disor-
ders; psoriasis vulgaris or atopic dermatitis. 
 Cellular factors that have significant roles in chemo-
therapy resistance include at least the following five 
mechanism : (1) changes in drug uptake or drug efflux 
across cell membrane or between cytoplasm and nu-
cleus (transport-mediated resistance), (2) changes in 
the activation or inactivation of drugs within the cell 
(metabolic resistance), (3) changes in targeted enzymes 
through altered levels of those targets within cells or 
through the altered affinity of cellular enzymes for 
the drug (target resistance), (4) changes in DNA repair 
processes, (5) changes in the ability of cells to execute 
programmed cell death or apoptotic mechanisms'. 
 P-Glycoprotein (P-gp), encoded by multi-drug resis-
tance 1 (MDR 1) z gene, is a transmembrane efflux 
pump for different lipophilic drugs including GC'. 
Thus upregulation of P-gp may provide a mechanism 
for reduced GC responses and GC induced cell 
apoptosis. To clarify whether P-gp plays a part in low 
responses to ordinal GC ointment in the patients with 
inflammatory skin disorders, we have examined P-gp 
expression and apoptosis in skin specimens from 
chronic inflammatory skin disorders such as psoriasis 
vulgaris or atopic dermatitis using a standard 
immunohistochemical technique. Furthermore, we ex-
amined MDR 1 gene expression using RT-PCR tech-
nique in skin specimens from psoriasis vulgaris.
Patients and Methods
Patients 
 Twenty-eight patients with psoriasis vulgaris and 
30 patients with atopic dermatitis were enrolled in 
this study. The samples and their assessment were 
shown in Table 1. Clinical assessment of psoriasis was
Table 1. Numbers of samples and thier assessment
           Psoriasis vulgaris Atopic dermatitis 
samples 28 specimens 30 specimens 
         (22 patients) (30 patients) 
assessment Psoriasis area and severity Severity index 
          index(PASI) (Japanese Dermatological Association)
made using PASI score' and atopic dermatitis using 
Severity Index proposed by Japanese Dermatological 
Association. 
 Nobody but one patient had received vitamin D3 
ointment therapy at biopsy time in psoriasis vulgaris 
patients. Before and after one month ointment with 
group I or II class GCS, clinical assessment was made. 
Responders were defined as patients with reducing 
scores below 75% compared with pretreatment scores', 
retrospectively. Low responders were defined as pa-
tients not corresponded to above. Patients were classi-
fied into four groups as described in summary. 
 Biopsied specimens were obtained from the patients 
under the informed consent before and after the treat-
ment with topical GC. Paraffin-embedded tissues for 
immunostaining had been routinely fixed in 10% neu-
tral. buffered formalin for 8-48 hours. Cryosections 
were preserved in -30°C until RNA extraction.
Antibodies 
 JSB-1 (NOVOCASTRA, Newcastle upon Tyne, UK), 
anti-P-gp antibody; it recognizes an internal epitope of 
PGP molecule'; the ascites was used in a dilution of 
1:20. Anti CD3 antibody (DAKO, Copenhagen, Denmark) 
or anti CD20 antibody (DAKO) was used in a dilution 
of 1:50 or 1:100. Terminal deoxynucleotidyl transferase 
(Tdt) enzyme (INTERGEN, Oxford,UK) was used for 
labelling apoptotic cells'. 
 Phosphate-buffered saline(PBS) (pH 7.4) containing 
bovine serum albumin (BSA) (1%) was used for the di-
lution of JSB-1.
Immunohistochemistry 
 Paraffin tissue sections of 5 p m were placed on 
siliconized glass slide and deparaffinized in xylene, 
100% ethanol, 90% ethanol for P-gp, anti CD3, anti 
CD20 staining or Tdt-mediated Unscheduled Nick End 
Labelling (TUNEL). 
 Staining with anti P-gp staining: The antigen re-
trieval was performed by treatment with the slides in 
90V citrate buffer for 20 minutes. After washing in 
aqua for 10 minutes, endogenous peroxidase activities 
were blocked in aqua bidest, containing 3% H202 for
5 minutes. Then the slides were washed in PBS for 10 
minutes. All tissue sections and positive controls' 
were incubated with JSB-1 for overnight at 4°C; nega-
tive controls, however, were incubated only with 1 % 
BSA. After washing in PBS for 10 minutes, all slides 
were covered with biotinylated gout antimouse IgG 
(DAKO), for 10 minutes at room temperature. The 
slides were then washed again for 10 minutes in PBS. 
Finally they were incubated for 10 minutes at room 
temperature with a streptavidin- biotin-conjugated 
peroxidase complex (DAKO). 
 Staining with anti-CD3 or CD20 staining: The anti-
gen retrieval was performed by treatment in 0.1% 
trypsin for 30 minutes at room temperature for anti 
CD3. After washing in PBS for 10 minutes, endoge-
nous peroxidase activities were blocked in aqua 
bidest, containing 3% H202 for 5 minutes. After wash-
ing in PBS for 10 minutes, the slides were incubated 
in 5% normal goat serum for 5minutes. All tissue sec-
tions and positive controls were incubated with anti 
CD3 or CD20 antibody for lh at 4°C; negative con-
trols, however, were incubated only with 1% BSA. 
After washing in PBS for 10 minutes, all slides were 
treated same as P-gp staining. 
 TUNEL method: The slides were treated with 20,u 
g/ml proteinase K in PBS for 1 hour at room tempera-
ture. Endogenous peroxidase activities were blocked in 
aqua bidest, containing 3% H202 for 5 minutes, same 
as P-gp staining. Then the slides were washed in PBS 
for 10 minutes and then treated with EQUILIBRATION 
BUFFER (INTERGEN, New York, USA) for 10 min-
utes. Then the slides were incubated with Tdt enzyme 
for 1 hour at 37 °C and further incubated with 
WORKING STRENGTH STOP/WASH BUFFER 
(INTERGEN) for 10 minutes at room temperature. 
Finally they were incubated for 30 minutes at room 
temperature with anti -digoxigenin peroxidase conju-
gate (INTERGEN). 
 The peroxidase label was developed for tissues 
using 0.03% H202 and 3,3'-diaminobenzidine tetrachlo-
ride (DAB), which results in a brown staining product. 
The tissue sections were mounted with Permount 
(Fisher Scientific, New Jersey, USA), and 
counterstaining with hematoxylin and methyl green 
for immunohistochemistry and TUNEL method, re-
spectively. 
 Semiquantitative immunohistochemical scores were 
defined; 0: no staining, 1: weakly positive, 2: moder-
ately positive, 3: strongly positive. Sweat gland of nor-
mal skin defined as score 16 for P-gp.
R T-PCR 
 Total cellular RNA was isolated using RNeasy Mini 
Kit (QIAGEN, California, USA) as described by Meller 
et al' RNA concentration and purity were determined 
spectrophotometrically 
 Total cellular RNA (500 ng) was amplified by RT 
PCR using Ready To GoTM RT-PCR Beads (Amersham 
Pharmacia Biotech, New Jersey, USA) with primers de 
scribed by Chen et al' (421C for 30 minutes to re 
verse transcribe and PCR cycles, an initial step of 95 
°C fo r 5 minutes, 45 cycles of a 3-temperature PCR 
[95°C for 1 minute, 62°C for 1 minute, 72°C for 1 min 
ute] and end with 72°C for 5 minutes Each PCR product 
was then size-fractionated through a 18% agarose gel 
The amplified cellular fragment (target) was 544 by 
 Further, RT PCR products were extracted and di 
gested with VSP I (Takara, Kyoto, Japan), digested al-




 In immunohistochemically, only sweat gland cells 
showed weakly positive staining of P gp in the normal 
skin (Fig la) In contrast, P gp was mainly expressed 
in the cytoplasm of infiltrated cells as well as 
keratinocyte and vascular endothelial cells in each 
samples obtained from psoriasis vulgaris or atopic der 
matitis patients The TUNEL positive cells showed a 
nuclear staining pattern in the lesinal skin of psoriasis 
vulgaris and atopic dermatitis 
  Patients profiles of psoriasis vulgaris are summa 
razed in Table 2 The mean age of S () group younger 
than other groups, but no significant differences were 
seen in other parameters 
 There was no significant correlation between 
immunohistochemical scores of P gp and ages, PASI 
scores, PUVA therapy, biopsy site nor complication of
Figure 1. This figure showed that a part of P gp positive cells were CD3 
positive cells (a)Only sweat gland cells showed weakly positive staining of 
P gp in the normal skin (x100) (b) Low magnification of P gp 
immunostaining of the sample from psoriasis vulgaris patient P gp mainly 
expressed in the cytoplasm, was observed in infiltrating cells as well as 
keratinocyte and vascular endothelial cells (x50) (c) P gp immunostaining 
from the another patient which showed a low intensity of P gp (x50) (d) 
P gp immunostaining of the sample from psoriasis vulgaris patient 
Mononuclear cells showed positive (x100) (e) CD3 staining of the same pa 
tients (x100)
Table 2. Patients profiles of psoriasis vulgaris
Parameters S(-) S(+) R(-) R(+) 
Number of subjects* 6 5 5 12 
Age (years) ± S.D.** 38.5±16.3 50.8±16.9 62.8±21.7 61.6±16.2 
Sex (m/f) 6/0 8/1 3/2 8/4 
DM or hyperlipidemia (+/-) 3/3 0/5 2/3 4/8 
Biopsy site (SEA***/non SEA) 1/6 2/3 4/1 1/11 
PUVA (+/-) 1/5 2/3 0/5 5/7
*: mean value of subjects , **: p<0.05, ***: SEA=sun exposured skin 
 S (-): responder to topical steroid without steroid ointment for one month at the time of biopsy. 
S (+): responder to topical steroid and under steroid therapy at the time of biopsy, R (-): low or 
non- responder to topical steroid without steroid therapy for one month at the time of biopsy, R 
(+): low-or non-responder to topical steroid and under steroid therapy at the time of biopsy.
Table 3. Atopic dermatitis paients characteristics
Parameter S(-) S(+) R(-) R(+) 
Number of subjects* 8 13 0 9 
Age (years)* ± S.D. 20.1±4.5 22.8±7.3 26.7±12.5 
Sex (m/f) 4/4 8/5 7/2 
Number of eosinophils ± S.D. 899.4±743.0 969.6±705.7 801.7±522.9 
Biopsy site (SEA***/non SEA) 4/4 7/6 5/4 
Red face** (+/-) 0/7 0/13 8/1
*: mean value of subjects, **: p<0.05***: SEA=sun exposured skin 
 S (-): responder to topical steroid without steroid ointment for one month at the time of biopsy, S (+): 
responder to topical steroid and under steroid therapy at the time of biopsy, R (-): low or non- responder to 
topical steroid without steroid therapy for one month at the time of biopsy, R (+): low-or non-responder to 
topical steroid and under steroid therapy at the time of biopsy.
Figure 3. TUNEL scores of the samples from psoriasis 
vulgaris patients. There was no differences between 4 groups 
 S (-): responder to topical steroid without steroid ointment 
for one month at the time of biopsy, S (+): responder to topi-
cal steroid and under steroid therapy at the time of biopsy, 
R (-): low or non- responder to topical steroid without steroid 
therapy for one month at the time of biopsy, R (+): low-or 
non-responder to topical steroid and under steroid therapy at 
the time of biopsy, in TUNEL scores.
Figure 2. In psoriasis vulgaris patients, immunohistochemical 
scores of P-gp were significantly higher in R(+) group than 
in other groups.
DM or hyperlipidemia at biopsy times (data not 
shown). 
 The immunohistochemical scores of P-gp and GC 
ointment duration were significantly higher in R(+) 
group than in other groups (Fig.2). There was no sig-
nificant differences between R(-) samples and S(+) nor 
S(-) samples. Expression of PGP was correlated with 
GC ointment duration (Correlation coefficient=0.584, 
p<0.05), but not ages at biopsy times. 
 A part of P-gp positive cells were mast cells or CD3
Figure 4. In atopic dermatitis patients, immunohistochemical 
scores of P-gp were significantly higher in R (+) group than 
S (-) group, but not S (+) group.
positive cells (Fig.lb-e) but not CD20 positive cell 
(data not shown). 
 There was no differences between 4 groups in 
TUNEL scores in psoriasis vulgaris (Fig.3). TUNEL 
scores of symptomless margin of the lesion had not 
differences from lesional scores.
 In case of atopic dermatitis, clinical profiles are 
summarized in Table 3. No other parameters but 
atopic red face had significant differences between 4 
groups. 
 There was no significant correlation between 
immunohistochmical scores and severity index, num-
ber of peripheral blood eosinophils, total IgE nor bi-
opsy site (data not shown). 
 The immunohistochemical scores of P-gp were sig-
nificantly higher in R (+) group than in S (-) group 
(Fig.4). There was no differences of P-gp scores be-
tween S (+) samples and R (-) nor R (+) samples. There 
was no significant differences between S (+) and R (+) 
group in GC ointment duration. Expression of P-gp 
was not correlated with GC ointment duration. 
 Same as in psoriasis vulgaris patients, a part of P-gp 
positive cells were mast cells or CD3 positive cells but 
not CD20 positive cell (data not shown). 
 There was no significant differences between 4 
groups in TUNEL scores in atopic dermatitis same as 
psoriasis vulgaris (data not shown).
Expression of MDR-1 mRNA 
 Samples from which showed strong P-gp intensity 
in immunohischemistry, demonstrated MDR 1 gene ex-
pression in RT-PCR (Fig. 5). RT-PCR products were di-
gested into almost 400bp and 150bp fragments by 
VSP-I (data not shown). MDR1 mRNA expression was 
upregulated in the patients with R (+) group but not 
in S (+) group of psoriasis vulgaris.
Figure 5. MDR 1 gene expression of the lesional skin from 
the patients with psoriasis vulgaris by RT-PCR. Samples 
with strong P-gp intensity demonstrated significant MDR-1 
gene expression. No.1,2,4: Sample from R (+) group, No. 3: 
Sample from S (+) group, No. 5: normal human non sun-
exposed skin, No. 6: negative control, M: Bio Marker
Discussion
 Although several side effects were recognizedl0, 
topical GC ointment is the most widely used medica-
tion in the treatment of skin disorders; psoriasis 
vulgaris" or atopic dermatitis". In the last decade, 
new type of skin manifestations, i.e., persistent 
erythema of the face (atopic red face) 12 or
"poikiloderma -like lesion on the neck"" , have been rec-
ognized in patients with atopic dermatitis, especially 
in Japan. Poikiloderma-like lesion on the neck could 
be attribute to chronic inflammation and delay of 
wound healing process, possibly caused by long-
standing topical GC therapy". Topical GC preparations 
are categorized into different potency groups by vaso-
constrictor (i.e., skin blanching) assay. However, this is 
subjective and dose not correlate perfectly with clini-
cal antiinflammatory effects, percutaneous absorption, 
or propensity for adverse effects". No correlation was 
seen between Lymphocyte stertoid sensitivity (LSS) 
parameters: maximal percentage inhibition of 
thymidine incorporation achived at the highest con-
centration of dexamethason (Imax) and the concentra-
tion of steroid at which thymidine incorporation is re-
duced to 50% of Imax value, and cutaenous 
vasoconstrictor response; suggested tissue differences 
in steroid sensitivity". Currently, there is no reliable 
and accessible method available for expressing GC po-
tency in a better way". 
 Other problems have been implicated about topical 
GC ointment, i.e., GC insensitivity. GC insensitivity 
was observed in the subset of asthmatic' or leukemic" 
patients : they showed low responses to ordinal GC 
therapy, but others showed good responses. Low re-
sponders are resistant to the antiinflammatory effect 
of GC while simultaneously showing several other side 
effects known to reflect normal sensitivity". 
 P-gp is a energy-deriven plasma membrane trans-
porter which pumps certain drugs including GC out of 
the cells". The physiologic role of P-gp is speculative, 
and the possibilities include the protection of normal 
tissues from environmental and endogenous toxins, 
steroid secretion in the adrenal gland, secretion of bile 
salts in the bile canaliculi, and secretary functions in 
the kidney'. Prolonged exposure of tumor cells to 
natural hydrophobic cytotoxic drugs may result in the 
acquisition of resistance by cells not only to the drugs 
used but also to a series of structurally and function-
ally unrelated drugs". 
 Recently, several reports have described relation be-
tween GC and P-gp in patients with asthma or nasal 
polyp. Henriksson et al." reported that nasal polyps 
from 5 of 17 patients treated with clinical dose of a 
topical nasal steroid showed a stronger staining inten-
sity for P-gp than polyps from 13 untreated patients. 
Montano et al.' showed that surface P-gp expression 
and Rh 123 efflux in B cells were decreased in GC 
sensitive asthma than in GC resistant patients or mild 
asthma, significantly. There was no significant differ-
ences between their GC sensitive and resistant pa-
tients in total daily steroid dose. Furthermore, they
observed reduced surface functional P-gp expression 
by B cells from normal volunteers after 48-h exposure 
of cells to 10 nM dexamethasone. 
 In our observation, intensity of P-gp and MDR 1 
gene expressions showed a positive correlation to the 
duration of GC application to the lesional skin in pso-
riasis vulgaris which might suggest that P-gp plays 
some role in induction of GC insensitivity as well 
asthma or nasal polyp patients. 
 In contrast to psoriasis vulgaris, there was no sig-
nificant colleration between P-gp scores and duration 
of steroid ointment in the patients with atopic derma-
titis; suggested atopic dermatitis occurred not only by 
inflammation but by impaired barrier function". 
 Several reports showed GC induces cell apoptosis22. 23 
However, in our patients, TUNEL scores were not sig-
nificantly different between 4 groups, and scores of 
most patients showed 0. Our data suggested that clini-
cal response to GC ointment in inflammatory skin dis-
eases was caused not by apoptotic but by another 
mechanism; i.e., downregulation of the expression of 
cytokines and adhesion molecules". 
 Maillefert et al. demonstrated that larger dose of GC 
induced higher expression of MDR 1 gene and P-gp in 
rheumatoid arthritis and suggested the possible resis-
tance to other drugs". In a similar manner to their ob-
servation, our data on psoriasis vulgaris suggested 
that GC ointment induces the expression of P-gp to re-
duce the response to other drugs. 
 In conclusion, we should pay careful attention for 
the possible induction of GC insensitivity in the pa-
tients with inflammatory skin disorders under GC 
ointment. Combination of phototherapy, vitamin D3 
ointment, or immunosuppressive agent with GC might 
prevent the induction of drug resistance as demon-
strated in combination chemotherapy for cancer pa-
tients.
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